Detailed clinical resources and information regarding Anticancer Therapies.
Hormonal Therapies
| Estrogen Endocrine Therapy | |
| GnRH agonist | Goserelin (Zoladex) – Leuprolide (Eligard, Lupron, Viadur) – Triptorelin (Decapeptyl) |
| AI (steroidal) | Exemestane (Aromasin) |
| AI (non-steroidal) | Anastrozole (Arimidex) – Letrozole (Femara) |
| Selective ER modulators (SERMs) | Raloxifene (Evista) – Tamoxifen (Nolvadex) – Toremifene (Fareston) |
| Selective ER down regulators (SERDs) | Elacestrant (Orserdu) – Fulvestrant (Faslodex) – Imlunestrant (Inluriyo) – Camizestrant (investigational) – Vepdegestrant (PROTAC ER degrader, investigational) |
| Androgen Deprivation Therapy (ADT) | |
| GnRH agonist | Buserelin (Suprefact) – Goserelin (Zoladex®) – Histrelin (Supprelin LA®, Vantas®) – Leuprolide (Eligard®, Lupron®) – Triptorelin (Trelstar®) |
| GnRH antagonist | Degarelix (Firmagon®) |
| Androgen Hormonal Therapy | |
| Antiandrogen (steroidal) | Cyproterone acetate |
| Antiandrogen (non-steroidal) (-amide) | Apalutamide (Erleada) – Bicalutamide (Casodex) – Darolutamide (Nubeqa) – Enzalutamide (Xtandi) – Flutamide (Eulexin) – Nilutamide (Nildandron) |
| CYP17 (Androgen biosynthesis) inhibitor | Abiraterone acetate (Zytiga) – Ketoconazole (n/a) |
| Somatostatin Analog | |
| Lanreotide (Somatuline Depot) – Octreotide (Bynfezia; Mycapssa; SandoSTATIN) | |
Chemotherapy
| Alkylating Agents | |
| Nitrogen mustards | Bendamustine (Treanda, Bendeka) – Chlorambucil (Leukeran) – CycloPHOSphamide (Cytoxan, Neosar) – Ifosfamide (Ifex) – Mechlorethamine (Topical for CTCL; Valchlor) – Melphalan (Alkeran, Evomela) – Melphalan flufenamide (Pepaxto; withdrawn 2022) |
| Nitrosureas | Carmustine (BiCNU, Gliadel Wafer [brain tumors]) – Lomustine (CeeNU, Gleostine) – Streptozocin (Zanosar) |
| Platinum analogs | CISplatin (Platinol) – CARBOplatin (Paraplatin) – Oxaliplatin (Eloxatin) |
| Triazenes | Dacarbazine (DTIC-Dome) – Temozolomide (Temodar) |
| Alkyl Sulfonates | Busulfan (Myleran PO, Busulfex IV) – Treosulfan |
| Ethyleneimines | Thiotepa (Tepadina) |
| Methylmelamine | Altretamine (Hexalen) |
| Methylhydrazine derivative | Procarbazine (Matulane) |
| Marine-derived / minor groove binders | Trabectedin (Yondelis), Lurbinectedin (Zepzelca for SCLC) |
| Antimetabolite Agents (CCS – S-Phase) | |
| Fluoropyrimidines | 5-Fluorouracil (Adrucil) – Capecitabine (Xeloda PO) – Floxuridine HAI – Trifluridine + Tipiracil (Lonsurf) |
| Cytidine Analogs (C) | Azacitidine (Vidaza) – Cytarabine (Conventional, Cytosar-U; Liposomal+Daunorubicin, Vyxeos) – Decitabine (Dacogen) – Gemcitabine (Gemzar) |
| Purines and Purine Antimetabolites | Cladribine (Leustatin) – Clofarabine (Clolar) – Fludarabine (Fludara) – Mercaptopurine (6-MP, Purinethol, Purixan PO) – Nelarabine (Arranon) – Pentostatin (Nipent) – Thioguanine (6-TG, Tabloid) |
| Antifolates | Methotrexate (Trexall, Rheumatrex, Otrexup, Rasuvo) – PEMEtrexed (Alimta) – PRALAtrexate (Folotyn) – Raltitrexed (Tomudex) |
| Ribonucleoside diphosphate reductase inh | Hydroxyurea (Droxia; Hydrea; Siklos) |
| Microtubule-Targeting Agents (CCS – M-Phase) | |
| Vinca alkaloids | VinBLAStine (Velban) – VinCRIStine (Oncovin) – Vindesine (Eldisine) – Vinorelbine (Navelbine) |
| Taxanes | Cabazitaxel (Jevtana) – DOCEtaxel (Taxotere) – PACLitaxel (Conventional; Taxol) – PACLitaxel (Protein Bound; nab-paclitaxel, Abraxane) |
| Halichondrins | Eribulin (Halaven) |
| Epothilone B analog | Ixabepilone (Ixempra) |
| Estradiol, nitrogen mustard, anti-microtubule | Estramustine (Emcyt) |
| ADC (microtubule-targeting warhead) | Brentuximab Vedotin (BV; Adcetris; antiCD30) – Mirvetuximab Soravtansine (MIRV; Elahere; Anti-FRα) – Ado-Trastuzumab Emtansine (T-DM1; Kadcyla; antiHER2) – Enfortumab Vedotin-ejfv (EV; Padcev; Anti-Nectin-4) – Tisotumab Vedotin-tftv (TV; Tivdak; Anti-TF) |
| Cytotoxic Antibiotics | |
| DNA break, ROS gen | Bleomycin (BLEO 15K) |
| DNA intercalation / RNA polymerase inhibition | DACTINomycin (Actinomycin D; Cosmegen) |
| Bioreductive alkylation | MitoMYcin C (Mutamycin) |
| Topoisomerase Inhibitors | |
| (TopoI) Campothecin analogs | Irinotecan (Camptosar) – Topotecan (Hycamtin) |
| (TopoII) Epipodophyllotoxin | Etoposide (Vepesid) – Etoposide phosphate (Etopophos) – Teniposide (Vumon) |
| (TopoII) Anthracyclines | DAUNOrubicin (Conventional) – DOXOrubicin (Conventional; Adriamycin) – DOXOrubicin (Liposomal) – EpiRUBicin – IDArubicin – MitoXANTRONE (Novantrone) – Valrubicin (Valstar) |
| (TopoI) ADC Anti-Trop-2 warhead | Sacituzumab Govitecan (Trodelvy), Datopotamab Deruxtecan (Datroway) |
| Protein Synthesis Inhibitors | |
| Cephalotaxine alkaloid (elongation inhibitor) | Omacetaxine (Synribo) |
| Enzymes | |
| Asparaginase (Erwinia [Recombinant]) (Rylaze) – Calaspargase Pegol (Asparlas) – Pegaspargase (Oncaspar) | |
Targeted Therapy
| EGFR Inhibitors | |
| Monoclonal antibodies | Cetuximab (Erbitux) – Necitumumab (Portazza) – Panitumumab (Vectibix) |
| First generation (reversible TKI) | Erlotinib (Tarceva) – Gefitinib (Iressa) |
| Second-Generation (irreversible EGFR/HER2 TKIs) | Afatinib (Gilotrif) – Dacomitinib (Vizimpro) – Lapatinib (Tykerb) –Neratinib (Nerlynx) – Vandetanib (Caprelsa) |
| Third-Generation (mutant-selective irreversible TKIs, T790M) | Lazertinib (Leclaza) – Osimertinib (Tagrisso) |
| EGFR Exon 20 Insertions TKI | Mobocertinib (Exkivity) – Sunvozertinib (Zegfrovy) |
| KRAS G12C-inhibitors | Adagrasib (Krazati) – Sotorasib (Lumakras) – Olomorasib (investigational) |
| Bispecific mAb EGFR/MET Exon 20 | Amivantamab-vmjw (Rybrevant) |
| Human Epidermal Growth Factor Receptor 2 (HER2, ERBB2 GENE, P185) Antagonists | |
| Monoclonal antibodies | Trastuzumab (Herceptin) – Ado-trastuzumab ematansine (Kadcyla) – Fam-trastuzumab deruxtecan-nxki (Enhertu) – Pertuzumab (Pertaja) – Zanidatamab-hrii (Ziihera) |
| Small molecules | Lapatinib (Tykerb) – Neratinib (Nerlynx) – Tucatinib (Tukysa) – Zongertinib (Hernexeos) |
| HER2/HER3 bispecific inh mAb | Zenocutuzumab (Bizengri) |
| Claudin 18.2 (CLDN18.2) Inhibitor | |
| Monoclonal antibodies | Zolbetuximab-clzb (Vyloy) |
| Anaplastic Lymphoma Kinase (ALK) Inhibitors | |
| First generation | Crizotinib (Xalkori) |
| Second generation | Alectinib (Alecensa) – Brigatinib (Alunbrig) – Ceritinib (Zykadia) |
| Third generation | Lorlatinib (Lorbrena) |
| ALK/ROS1 inhibitor | Taletrectinib (Ibtrozi) – Entrectinib (Rozlytrek) |
| Neurotrophic tyrosine receptor kinase (NTRK) Inhibitors | |
| TrkA, TrkB, TrkC inhibitor | Larotrectinib (Vitrakvi) |
| Dual NTRK/ROS1 inhibitor | Entrectinib (Rozlytrek) – Repotrectinib (Augtyro) |
| BRAF Inhibitors | |
| TKI inhibitors | Dabrafenib (Tafinlar) – Encorafenib (Braftovi) – Vemurafenib (Zelboraf) – Tovorafenib (Ojemda) |
| Mitogen-activated protein kinase (MEK) Inhibitors | |
| KI inhibitors | Binimetinib (Mektovi) – Cobimetinib (Cotellic) – Mirdametinib (Gomekli) – Selumetinib (Koselugo) – Trametinib (Mekinist) |
| RAF/MEK, FAK/Pyk2i, RAF/MEK | Avutometinib (novel RAF/MEK clamp) + Defactinib (FAK/Pyk2i) (Avmapki Fakzynja) |
| Mammalian Target Of Rapamycin (mTOR) Inhibitors | |
| Rapalogs | Everolimus (Afinitor) – Sirolimus – Temsirolimus (Torisel) |
| Dual pan-PI3K/mTORC1/2i | Gedatolisib (investigational) |
| Phosphatidylinositol 3-Kinase (PI3K) Inhibitors | |
| (α) Small molecule | Alpelisib (Piqray) – Inavolisib (Itovebi) |
| (α/δ) Small molecule | Copanlisib (Aliqopa) |
| (δ/γ) Small molecule | Duvelisib (Copiktra) |
| (δ) Small molecule | Idelalisib (Zydelig) |
| (δ/ε) Small molecule | Umbralisib (Ukoniq) |
| Dual pan-PI3K/mTORC1/2i | Gedatolisib (investigational) |
| Proteasome Inhibitors (PI) | |
| First generation | Bortezomib (Velcade) |
| Second generation | Carfilzomib (Kyprolis), Ixazomib (Ninlaro) |
| AKT Inhibitors | |
| TKI inhibitors | Capivasertib (Truqap) |
| Vascular Endothelial Growth Factor (VEGF) Inhibitors | |
| Monoclonal antibodies (-mab) | Bevacizumab (Avastin) – Ramucirumab (Cyramza) |
| Recombinant fusion protein (-cept) | Ziv-aflibercept (Zaltrap) |
| Small molecules (target TKI; -nib) | Axitinib (Inlyta) – Cabozantinib (Cabometyx, Cometriq) – Fruquintinib (Fruzaqla) – Lenvatinib (Lenvima) – Pazopanib (Votrient) – Regorafenib (Stivarga; targets RAF TKI) – Sorafenib (Nexavar) – Suntinib (Sutent) – Tivozanib (Fotivda) – Vandetanib (Capresla) |
| MET Inhibitors | |
| TKI inhibitors | Capmatinib (Tabrecta) – Crizotinib (Xalkori) – Tepotinib (Tepmetko) |
| Bispecific mAb EGFR/MET Exon 20 | Amivantamab-vmjw (Rybrevant) |
| ADC anti-cMet mAb | Telisotuzumab Vedotin (Emrelis) |
| Fibroblast Growth Factor Receptor (FGFR) Inhibitors | |
| mAb, HER2, GEJ | Bemarituzumab (investigational) |
| TKI inhibitor | Erdafitinib (Balversa) – Futibatinib (Lytgobi) – Infigratinib (Truseltiq) – Pemigatinib (Pemazyre) |
| RET Kinase Inhibitors | |
| TKI inhibitor | Pralsetinib (Gavreto) – Selpercatinib (Retevmo) |
| PDGFR-Alpha Blocker | |
| Monoclonal antibody | Olaratumab (Lartruvo) |
| Small molecules, TKI inhibitors | Avapritinib (Ayvakit) – Ripretinib (Qinlock; KIT inhibitor) |
| CDK 4/6 Inhibitors | |
| Small molecule | Abemaciclib (Verzenio®) – Palbociclib (Ibrance®) – Ribociclib (Kisqali®) |
| Aurora A Kinase (AURKA) Inhibitors | |
| Reversible, ATP-competitive, selective | Alisertib (investigational) |
| BCL2 Inhibitors | |
| Venetoclax (Venclexta) | |
| Poly (ADP-ribose) Polymerase (PARP) Inhibitors | |
| TKI inhibitors | Niraparib (Zejula) – Olaparib (Lynparza) – Rucaparib (Rubraca) – Talazoparib tosylate (Talzenna) |
| BCR-ABL Inhibitors | |
| First-generation TKI | Imatinib (Gleevec) |
| Second generation TKI | Dasatinib (Sprycel) – Nilotinib (Tasigna) – Bosutinib (Bosulif) |
| Third generation TKI | PONATinib (Iclusig; T315I mutation) |
| TKI-STAMP inhibitor | Asciminib (Scemblix) |
| Bruton Tyrosine Kinase (BTK) Inhibitors | |
| 1st gen TKI (covalent/irreversible) | Ibrutinib (Imbruvica) |
| 2nd gen TKI (covalent/irreversible) | Acalabrutinib (Calquence) – Zanubrutinib (Brukinsa) – Tirabrutinib (Velexbru, investigational) – Orelabrutinib (Hibruka, Yinuokai, investigational) |
| 3rd gen TKI (noncovalent) | Pirtobrutinib (Jaypirca) |
| Dual BTK/LYNi (noncovalent) | Birelentinib (investigational) |
| Janus Kinase (JAK) Inhibitors | |
| Selective JAK2i TKI | VGT1849B (investigational) |
| Dual JAK1/2 TKI | Momelotinib (Ojjaara) – Ruxolitinib (Jakavi) |
| Dual FLT3/JAK2i | Fedratinib (Inrebic) – Pacritinib (Vonjo) |
| FLT3 Inhibitors | |
| Class I (ITD-/TKD-mutations) | Gilteritinib (Xospata) – Midostaurin (Rydapt) |
| Class II (ITD-mutations) | Quizartinib (Vanflyta) |
| Dual FLT3/JAK2i | Fedratinib (Inrebic) – Pacritinib (Vonjo) |
| CSF-1R Inhibitors | |
| Monoclonal antibody | Axatilimab-csfr (Niktimvo) |
| TKI inhibitors | Pexidartinib (Turalio) – Vimseltinib (Romvimza) |
| Histone Deacetylase (HDAC) Inhibitors | |
| Belinostat (Beleodaq) – Panobinostat (Farydak) – RomiDEPsin (Istodax) – Vorinostat (Zolinza) | |
| Histone Methyltransferase (HMT) Inhibitors | |
| EZH2 inhibitor | Tazemetostat (Tazverik) |
| Menin Inhibitors | |
| Menin-KMT2A interaction inhibitor | Revumenib (Revuforj) |
| IDH1 Inhibitors | |
| Ivosidenib (Tibsovo) – Olutasidenib (Rezlidhia) | |
| IDH2 Inhibitors | |
| Enasidenib (IDHIFA) | |
| IDH1/2 Inhibitors | |
| Vorasidenib (Voranigo) | |
| Selective Inhibitor Of Nuclear Export (SINE) | |
| Selinexor (Xpovio) | |
| Gamma Secretase Inhibitors | |
| Nirogacestat (Ogsiveo) | |
| Ornithine Decarboxylase Inhibitors | |
| Eflornithine (Iwilfin) | |
| Glutaminase Inhibitors | |
| Telaglenastat (investigational) | |
| Hepcidin Mimetic Peptides (Iron Regulators) | |
| Rusfertide (investigational) | |
| HIF-2alpha Inhibitors | |
| Belzutifan (Welireg) | |
| Hedgehog Pathway Inhibitors | |
| Glasdegib (Daurismo) – Sonidegib (Odomzo) – Vismodegib (Erivedge) | |
| Telomerase Inhibitors | |
| Imetelstat (Rytelo) – Ateganosine (2′‑Deoxythioguanosine, investigational) | |
| Selective Immunomodulating Microtubule-Binding Agent (SIMBA) | |
| Plinabulin (investigational) | |
| Protease Activator Therapies (Oncogenic Stress Modulators) | |
| Dordaviprone (Modeyso) | |
| Targeted Protein Modification | |
| Degrader (PROTAC) | Vepdegestrant (SERDs, investigational) |
| Rewires (RIPTAC) | HLD-0915 (investigational) |
Immunotherapy
| Immune Checkpoint Inhibitors (ICI; CTLA-4, PD-1, PD-L1) | |
| CTLA-4 inhibitors | Ipilimumab (Yervoy®) – Tremelimumab-actl (Imjudo) |
| PD-1 inhibitors | Cemiplimab-rwlc (Libtayo®) – Dostarlimab-gxly (Jemperli) – Nivolumab (Opdivo®) – Pembrolizumab (Keytruda) – Pembrolizumab and Berahyaluronidase (Keytruda Qlex) – Penpulimab (Anniko) – Retifanlimab (Zynyz) – Tislelizumab-jsgr (Tevimbra) – Toripalimab (Loqtorzi) |
| PD-L1 inhibitors | Atezolizumab (Tecentriq®) – Avelumab (Bavencio®) – Cosibelimab (Unloxcyt) – Durvalumab (Imfinzi®) |
| Dual LAG-3i/PD-1i | Nivolumab and Relatlimab (Opdualag) |
| CD47i fusion protein | Evorpacept (ALX148, investigational) |
| Bispecific PD-1/VEGFi | Ivonescimab (investigational) |
| Bispecific PD-L1/VEGFi | Pumitamig (investigational) |
| Anti-TIGIT Antibody | |
| Ociperlimab (investigational) | |
| Bispecific T-Cell Engager (BiTE) Therapy | |
| Anti-BCMA/CD3; mAb | Elranatamab (Elrexfio) – Teclistamab-cqyv (Tecvayli) – Linvoseltamab (Lynozyfic) – Alnuctamab (Investigational) |
| Anti-CD19/CD3; mAb | Blinatumomab (Blincyto) |
| Anti-CD20/CD3; mAb | Epcoritamab (Tepkinly) – Glofitamab (Columvi) – Mosunetuzumab (Lunsumio) – Cevostamab (investigational) – Odronextamab (investigational) |
| Anti-GPRC5D/CD3; mAb | Talquetamab (Talvey) |
| Anti-gp100/CD3; rfp recombinant fusion protein | Tebentafusp (Kimmtrak) |
| Anti-Delta-like ligand 3 (DLL3)/CD3; mAb | Tarlatamab (Imdelltra) |
| Trispecific T-Cell Engager (TRiTE) Therapy (investigational) | |
| CD3, CD19, CD28 | CC312 (ongoing trial) |
| CD3, CD38, CD28 | SAR442257 (ongoing trial) |
| CD3, BCMA, CD38 | ISB-2001 (ongoing trial) |
| CD3, DLL3, albumin | MK-6070 (formerly HPN328; ongoing trial) |
| CD3, BCMA, albumin | HPN217 (ongoing trial) |
| CD3, EpCAM, block | HPN601 (ongoing trial) |
| CD3, CD79b, CD20 | JNJ-8543 (ongoing trial) |
| CD3, BCMA, GPRC5D | JNJ-5322 (ongoing trial) |
| CD3, CD19, CD22 | AZD5492 (ongoing trial) |
| CD3, DLL3, PDL1 | ZG006 (ongoing trial) |
| Anti-CD19 | |
| mAb | Tafasitamab-cxix (Minjuvi) |
| Anti-CD20 | |
| mAb | Ibritumomab Tiuxetan (Zevalin) – Obinutuzumab (Gazyva) – Ofatumumab (Arzerra) – RiTUXimab (Rituxan, MabThera) |
| Anti-CD22 | |
| mAb | Moxetumomab pasudotox-tdfk (Lumoxiti) |
| Anti-CD38 | |
| mAb | Daratumumab (Darzalex, Darzalex Faspro as SC combo with hyaluronidase) – Isatuximab-irfc (Sarclisa) |
| Anti-CD52 | |
| mAb | Alemtuzumab (Campath, Lemtrada) |
| Anti-SLAMF7 | |
| mAb | Elotuzumab (Empliciti) |
| Anti-GD2 | |
| mAb | Dinutuximab (Ch14.18; Unituxin) and Dinutuximab beta (Qarziba) – Naxitamab (Danyelza) |
| Anti-CC Chemokine Receptor 4 (CCR4) Antibody | |
| mAb | Mogamulizumab-kpkc (Poteligeo) |
| Antibody-Drug Conjugate (ADC) | |
| Anti-BCMA | Belantamab Mafodotin-blmf (Blenrep; withdrawn as it did not meet primary endpoint in DREAMM-3 PhIII) |
| Anti-B7-H3 (CD276) | Ifinatamab Deruxtecan (I-DXd, investigational) |
| Anti-CD19 | Loncastuximab Tesirine-lpyl (Zynlonta) |
| Anti-CD22 | Inotuzumab Ozogamicin (Besponsa) |
| Anti-CD30 | Brentuximab Vedotin (Adcetris) |
| Anti-CD33 | Gemtuzumab Ozogamicin (Mylotarg) |
| Anti-CD79B | Polatuzumab Vedotin (Polivy) |
| Anti-CDH17 | 7MW4911 (investigational) |
| Anti-cMet | Telisotuzumab Vedotin (Emrelis) |
| Anti-Folate Receptor α | Mirvetuximab Soravtansine (Elahere) – Rinatabart Sesutecan (Rina-S, investigational) |
| Anti-HER2 | Ado-Trastuzumab Emtansine (Kadcyla) – Fam-Trastuzumab Deruxtecan (Enhertu) – Trastuzumab pamirtecan (BNT323, investigational) |
| Anti-Nectin-4 | Enfortumab Vedotin (Padcev) |
| Anti-Tissue Factor | Tisotumab Vedotin-tftv (Tivdak) |
| Anti-Trop-2 | Sacituzumab Govitecan (Trodelvy), Datopotamab Deruxtecan (Datroway) |
| Bispecific (EGFR x HER3) | Izalontamab Brengitecan (Iza-bren, investigational) |
| Peptide-Drug Conjugate (PDC) | |
| Anti-SORT1 | PQ203 (investigational) |
| Cellular Therapies | |
| CAR-T BCMA | Ciltacabtagene autoleucel (Cilta-cel, Carvykti) – Idecabtagene vicleucel (Abecma) |
| CAR-T CD19 | Tisagenlecleucel (Kymriah) – Axicabtagene ciloleucel (Yescarta) – Brexucabtagene autoleucel (Tecartus) – Lisocabtagene maraleucel (Breyanzi) – Obecabtagene autoleucel (Aucatzyl) |
| CAR-T EGFR | CARv3-TEAM-E |
| Tumor-Infiltrating Lymphocyte (TIL) | Lifileucel (Amtagvi) |
| TCR MAGE-A4 antigen | Afamitresgene Autoleucel (Tecelra; C-144-01 study) |
| Vaccine | Sipuleucel-T |
| Gene Therapy | Atidarsagene Autotemcel (Lenmeldy) – Betibeglogene Autotemcel (Zynteglo) – Elivaldogene Autotemcel (Skysona) – Exagamglogene Autotemcel (Casgevy) – Lovotibeglogene Autotemcel (Lyfgenia) |
| Immunomodulators | |
| Small molecule | Lenalidomide (Revlimid) – Pomalidomide (Pomalyst) – Thalidomide (Thalomid) |
| Biological Response Modulators | |
| IL-2 | Aldesleukin (Proleukin) |
| IL-15 | Nogapendekin Alfa Inbakicept (Anktiva, Adstiladrin) |
| Vaccine | BCG (Intravesical) (TICE BCG) |
| Interferon/Pegs | Interferon Alfa-2b (Intron A) – Peginterferon Alfa-2a (Pegasys) – Peginterferon Alfa-2b (Pegintron D/C) – Ropeginterferon Alfa-2b (Besremi) |
| IL2/CD25i | Denileukin Diftitox |
| Anti-CD123 | Tagraxofusp (Elzonris) |
| Mannan-binding lectin-Associated Serine Protease-2 (MASP-2) Inhibitor – (Complement Modulation) | |
| mAb complement inh | Narsoplimab (investigational) |
| Oncolytic Virus | |
| Genetically engineered | Talimogene Laherparepvec (T-VEC, Imlygic) |
| Stem-cell loaded viral tx | CLD-201 (SuperNova; investigational) |
Genetic Therapy
| Gene Therapy (Biologic Response Modifier) | |
| human interferon alpha 2B (IFNα2b) | Nadofaragene firadenovec-vncg (Adstiladrin®) |
Differentiation Therapy
| Arsenic Derivative | |
| Arsenic trioxide (Trisenox) | |
| Retinoids | |
| Retinoic Acid Derivative | Alitretinoin (Panretin) – Bexarotene (Targretin) – Isotretinoin (Absorica; Accutane; Amnesteem; Claravis; Clarus; Epuris; Myorisan [DSC]; Zenatane) – Tretinoin (ATRA, Vesanoid) |
| Retinoid-Like Compound | Acitretin (Soriatane) |
Radiopharmaceutical
Supportive Therapy
| RANK Ligand Inhibitors (Bone Health) | |
| Denosumab (Prolia, Xgeva) | |
| Bisphosphonate (Bone Health) | |
| Alendronate (Binosto, Fosamax) – Clodronate (Clasteon) – Ibandronate (Boniva) – Pamidronate (Aredia) – Risedronate (Actonel; Atelvia) – Zoledronic Acid (Reclast, Aclasta, Zometa) | |
| Hypoxia-Inducible Factor (HIF) Modulators (Anemia) | |
| Roxadustat (Evrenzo) | |